Galactomannan Is a Biomarker of Fosmanogepix (APX001) Efficacy in Treating Experimental Invasive Pulmonary Aspergillosis.


Journal

Antimicrobial agents and chemotherapy
ISSN: 1098-6596
Titre abrégé: Antimicrob Agents Chemother
Pays: United States
ID NLM: 0315061

Informations de publication

Date de publication:
20 12 2019
Historique:
received: 28 09 2019
accepted: 25 10 2019
pubmed: 7 11 2019
medline: 1 9 2020
entrez: 6 11 2019
Statut: epublish

Résumé

Galactomannan (GM) detection in biological samples has been shown to predict therapeutic response by azoles and polyenes. In a murine invasive pulmonary aspergillosis model, fosmanogepix or posaconazole treatment resulted in an ∼6- to 7-log reduction in conidial equivalents (CE)/g lung tissue after 96 h versus placebo. Changes in GM levels in BAL fluid and serum mirrored reductions in lung CE, with significant decreases seen after 96 h or 72 h for fosmanogepix or posaconazole, respectively (

Identifiants

pubmed: 31685475
pii: AAC.01966-19
doi: 10.1128/AAC.01966-19
pmc: PMC7187618
pii:
doi:

Substances chimiques

Antifungal Agents 0
Biomarkers 0
Mannans 0
Triazoles 0
galactomannan 11078-30-1
posaconazole 6TK1G07BHZ
Galactose X2RN3Q8DNE

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2019 Gebremariam et al.

Références

Antimicrob Agents Chemother. 2018 Jul 27;62(8):
pubmed: 29891599
Antimicrob Agents Chemother. 2001 Dec;45(12):3474-81
pubmed: 11709327
Antimicrob Agents Chemother. 2012 Feb;56(2):960-71
pubmed: 22143530
J Biol Chem. 2003 Jun 27;278(26):23639-47
pubmed: 12714589
ACS Chem Biol. 2012 Sep 21;7(9):1520-8
pubmed: 22724584
Antimicrob Agents Chemother. 2004 May;48(5):1908-11
pubmed: 15105158
Front Microbiol. 2018 Apr 04;9:661
pubmed: 29670608
mBio. 2017 Aug 22;8(4):
pubmed: 28830945
Antimicrob Agents Chemother. 2019 Jan 29;63(2):
pubmed: 30455238
Antimicrob Agents Chemother. 2019 Jan 29;63(2):
pubmed: 30455236
Mol Microbiol. 2003 May;48(4):1029-42
pubmed: 12753194

Auteurs

Teclegiorgis Gebremariam (T)

The Lundquist Institute for Biomedical Innovations, Torrance, California, USA.

Sondus Alkhazraji (S)

The Lundquist Institute for Biomedical Innovations, Torrance, California, USA.

Yiyou Gu (Y)

The Lundquist Institute for Biomedical Innovations, Torrance, California, USA.

Shakti Singh (S)

The Lundquist Institute for Biomedical Innovations, Torrance, California, USA.

Abdullah Alqarihi (A)

The Lundquist Institute for Biomedical Innovations, Torrance, California, USA.

Karen Joy Shaw (KJ)

Amplyx Pharmaceuticals Inc., San Diego, California, USA kshaw@amplyx.com ibrahim@lundquist.org.

Ashraf S Ibrahim (AS)

The Lundquist Institute for Biomedical Innovations, Torrance, California, USA kshaw@amplyx.com ibrahim@lundquist.org.
David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California, USA.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH